Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The trial also demonstrated significant improvements across multiple secondary endpoints
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
MoU to deploy Qure.ai’s chest X-ray solution across 20 government facilities aims to improve early detection in urban and rural populations
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
Subscribe To Our Newsletter & Stay Updated